
The study aimed to evaluate if a combination treatment of navigated central retinal laser and aflibercept lowered the treatment burden in these patients. The study evaluated 41 eyes of 41 patients with a mean age of 69.6 years. In treatment‐naïve BRVO patients, the addition of navigated central laser to aflibercept did not lower the treatment burden or affect functional or anatomical outcomes.
Like
Save
Share